Acute Coronary Syndrome, Dyslipidemias
Conditions
Brief summary
Recent trials have demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular adverse events following acute coronary syndrome (ACS). However, the data coming from the real-world setting are limited. Therefore, the aim of the study is to assess the association between LDL-C changes with prognosis in patients who survive ACS. Patients with ACS will be followed for mortality and major events for at least 1 year. Changes in LDL-C between the ACS and a 6- to 10-week follow-up visit will be analysed. The associations between quartiles of LDL-C change and therapy intensity with outcomes will be investigated using adjusted Cox regression analyses.
Interventions
DRUGStatin
Statin +/- ezetimib +/- Alirocumab
Sponsors
University Clinical Centre of Republic of Srpska
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* acute coronary syndrome
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major Cardiovascular Adverse Events | 1 year | All-cause death, Acute Coronary Syndrom, Need for Myocardial Revascularization |
Secondary
| Measure | Time frame |
|---|---|
| LDL reduction | 1 year |
Countries
Bosnia and Herzegovina
Contacts
Primary ContactBojan M Stanetic, MD, PhD
Backup ContactTamara S Kovacevic-Preradovic, MD, PhD
Outcome results
None listed